Furthermore, the effects of the potential inhibitor of several solute carriers, for example probenecid, on monocytic SLCO2B1 and pro-atherosclerotic events are not clear and were not tested here, but may offer an interesting therapy in decreasing the uremic effects in CKD patients. Here, SLCO2B1 is linked to chronic kidney disease.